Interesting perspective, Saman Hagh Gooie. CereGate was included in our report. We would welcome a conversation about how to measure IP strength and build a meaningful portfolio. Let’s keep the conversation going. We are tagging our Chief IP Officer, Will R..
We read the recent PatentVest post on the #BCI field with interest, but were surprised CereGate was omitted from the ranking - so we took the liberty to run some deep research ourselves. Our consensus analysis positioned CereGate 6th in overall IP strength among BCI companies, with 33 filings focused on adaptive algorithms and sensory substitution interfaces. By synthesizing two independent patent landscape reports, we evaluated companies on three key metrics: Total patent volume, Geographic breadth, and Strategic impact. The top spots went to ONWARD Medical (massive 380+ portfolio), Synchron (10-jurisdiction reach), and Neuralink (100+ BCI-specific filings). INBRAIN Neuroelectronics ranked surprisingly high (4th) despite fewer filings due to their exclusive graphene electrode patents. In terms of jurisdictional breadth, Synchron leads with coverage across 10 jurisdictions (US, EU, Asia, Australia), followed by Neuralink with filings in multiple regions via PCT (US, EU, JP, KR, CA, AU). Paradromics stands out for notably including China alongside Western markets, while CereGate shows moderate breadth focused on EU and US markets. Notable portfolio characteristics include ONWARD Medical's position as the largest overall neurotech IP estate (~380+ filings), INBRAIN Neuroelectronics's quality-over-quantity approach with exclusive graphene IP, and CereGate's software-focused portfolio that complements hardware-focused players. #Neurotechnology #Intellectualproperty #Patentlandscape #BCI #innovation